These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21254947)

  • 1. Pharmacotherapy for squamous-cell carcinoma of the head and neck.
    Papaspyrou G; Werner JA; Dietz A
    Expert Opin Pharmacother; 2011 Feb; 12(3):397-409. PubMed ID: 21254947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway.
    Lau PC; Chan AT
    Anticancer Drugs; 2011 Aug; 22(7):665-73. PubMed ID: 21709616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel targeted therapies in head and neck cancer.
    Ferreira MB; Lima JP; Cohen EE
    Expert Opin Investig Drugs; 2012 Mar; 21(3):281-95. PubMed ID: 22239178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma.
    Kanazawa T; Misawa K; Carey TE
    Expert Opin Ther Targets; 2010 Mar; 14(3):289-302. PubMed ID: 20148716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review.
    Murdoch D
    Curr Opin Oncol; 2007 May; 19(3):216-21. PubMed ID: 17414639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging molecular targeted therapies in the treatment of head and neck cancer.
    Bozec A; Peyrade F; Fischel JL; Milano G
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):299-310. PubMed ID: 19519286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
    Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study.
    Yoo GH; Lin HS; Iskander AJ; Piechocki MP; Oliver J; Kewson D; Lonardo F; Tainsky MA; Kim HR; Kim H; Ensley JF
    Laryngoscope; 2005 Nov; 115(11):1938-46. PubMed ID: 16319602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S; Grandis JR
    J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 as a therapeutic target in head and neck squamous cell carcinoma.
    Pollock NI; Grandis JR
    Clin Cancer Res; 2015 Feb; 21(3):526-33. PubMed ID: 25424855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
    Azoury SC; Gilmore RC; Shukla V
    Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
    Gilbert J; Argiris A
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):611-9. PubMed ID: 17099619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
    Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M
    Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of head and neck squamous cell carcinoma.
    Pan Q; Gorin MA; Teknos TN
    Expert Opin Pharmacother; 2009 Oct; 10(14):2291-302. PubMed ID: 19663637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
    Corvò R
    Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
    Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations.
    Martinez JC; Otley CC; Okuno SH; Foote RL; Kasperbauer JL
    Dermatol Surg; 2004 Apr; 30(4 Pt 2):679-86. PubMed ID: 15061855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
    Cooper JB; Cohen EE
    Head Neck; 2009 Aug; 31(8):1086-94. PubMed ID: 19378324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.